Anti-inflammatory and immunomodulatory activities of ruxolitinib were documented by normalization of blood cell subsets, dampening of inflammatory cell activation, and decrease of inflammatory cytokines and CRP levels, providing clues to the immunoregulatory effects of ruxolitinib in COVID-19 patients. This evidence concerns the gene CRP and COVID-19.